Glutathione vs NAD+: A Research Reference
Two compounds, two separate research records. This reference sets Glutathione and NAD+ against each other on parameters a laboratory can independently verify.
Compound profiles
Glutathione in the indexed record
The literature on Glutathione is an extensive body of work: 206,082 PubMed-indexed records, alongside 1,156 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Altern Ther Health Med, Annu Rev Biochem, Antioxid Redox Signal, spanning 1983–2024.
- The antioxidant glutathione — Vitam Horm, 2023. PMID: 36707132
- The Glutathione Theory of Aging — Altern Ther Health Med, 2024. PMID: 39316535
- Glutathione — Annu Rev Biochem, 1983. PMID: 6137189
- Glutathione: subcellular distribution and membrane transport (1) — Biochem Cell Biol, 2019. PMID: 30427707
NAD+ in the indexed record
Searching NAD+ against the PubMed index returns 76,583 records, an extensive evidence base, alongside 749 registered studies on ClinicalTrials.gov.
Journals represented in the current index include Cell Metab, EMBO Mol Med, Nat Metab, spanning 2020–2024.
- NAD(+) metabolism and its roles in cellular processes during ageing — Nat Rev Mol Cell Biol, 2021. PMID: 33353981
- NAD(+) metabolism, stemness, the immune response, and cancer — Signal Transduct Target Ther, 2021. PMID: 33384409
- NAD(+) homeostasis in health and disease — Nat Metab, 2020. PMID: 32694684
- NAD(+) homeostasis in human health and disease — EMBO Mol Med, 2021. PMID: 34041853
How the literature differs
The indexed record is not symmetrical between these two compounds. Glutathione carries 129,499 more indexed records than NAD+, which means published methodology, characterisation data and replication attempts are more readily located for Glutathione. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (1,156 vs 749) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | Glutathione | NAD+ |
|---|---|---|
| PubMed indexed records | 206,082 | 76,583 |
| Registered studies (ClinicalTrials.gov) | 1,156 | 749 |
| Literature depth | Extensive | Extensive |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Glutathione and NAD+ sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Glutathione describes conditions validated for Glutathione: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to NAD+ without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Selecting between them for a study design
Glutathione and NAD+ are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Glutathione) generally offers more methodological precedent.
Laboratory handling
Both compounds ship as lyophilised powder. Convention is storage of the sealed vial at -20°C away from light, with reconstitution immediately before experimental use. In solution, peptides are materially less stable than in lyophilised form.
Freeze-thaw cycling degrades integrity; aliquoting after reconstitution avoids repeatedly cycling one vial.
Frequently asked questions
Are Glutathione and NAD+ the same compound?
No. They are structurally distinct research compounds with separate literature records — 206,082 indexed records for Glutathione and 76,583 for NAD+.
Which of Glutathione or NAD+ has more published research?
Glutathione, with 206,082 indexed PubMed records against 76,583.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Related references
- Glutathione — product and lot documentation
- NAD+ — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.